

The path to cheaper and safer drugs: revamping the pharmaceutical industry in light of GlaxosmithKline's settlement

Falit B.

Journal of law, medicine and ethics

2005; 33(1):174-179

ARTICLE IDENTIFIERS

DOI: unavailable

PMID: 15934676

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: 93657473

pISSN: 1073-1105

eISSN: 1748-720X

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: 9315583

This article was identified from a query of the SafetyLit database.